Table 4.
Prognostic factors of overall survival from brain metastases diagnosis.
| Variables | n | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| Median (months) | p value | HR | 95% CI | p value | ||
| Gender | 0.98* | 0.67 | ||||
| Male | 53 | 3.9 | 1 | |||
| Female | 30 | 4.1 | 0.9 | 0.5-1.5 | ||
| Age at BM diagnosis# | 83 | 0.03* | 1.0 | 1.0-1.0 | 0.82 | |
| Site of primary tumor (n=79) | 0.05* | 0.20 | ||||
| Colon | 45 | 4.6 | 1 | |||
| Rectum | 34 | 2.8 | 1.4 | 0.8-2.4 | ||
| Tumor grade (n=71) | 0.59 | |||||
| Well or moderately differentiated | 62 | 3.7 | ||||
| Poorly differentiated | 9 | 4.6 | ||||
| Primary tumor resection | 0.74 | |||||
| Yes | 73 | 3.7 | ||||
| No | 10 | 3.9 | ||||
| ECOG PS at BM diagnosis | <0.01* | 0.03 | ||||
| 0 or 1 | 42 | 6.8 | 1 | |||
| 2 or 3 | 38 | 3.1 | 2.1 | 1.1-4.0 | ||
| RAS status | 0.66 | |||||
| Wild-type | 30 | 3.6 | ||||
| Mutant | 48 | 4.1 | ||||
| BRAF status | 0.04* | 0.38 | ||||
| Wild-type | 73 | 4.1 | 1 | |||
| Mutant | 5 | 3.3 | 1.7 | 0.5-5.6 | ||
| Site of BM | 0.01* | 0.27 | ||||
| Supratentorial only | 48 | 4.3 | 1 | |||
| Subtentorial only | 17 | 4.6 | 0.6 | 0.3-1.3 | ||
| Supra and subtentorial | 18 | 2.8 | 1.2 | 0.5-2.9 | ||
| Number of brain metastases | <0.01* | 0.13 | ||||
| Single | 42 | 6.2 | 1 | |||
| Multiple | 41 | 3.1 | 1.7 | 0.9-3.2 | ||
| Interval between PT and BM diagnosis | 0.20 | |||||
| Synchronous | 6 | 11.7 | ||||
| Metachronous | 77 | 3.9 | ||||
| Interval between BM and extracranial disease (n=75) | 0.11 | |||||
| Synchronous | 15 | 6.3 | ||||
| Metachronous | 60 | 3.7 | ||||
| Lung metastases at BM diagnosis | <0.01* | 0.02 | ||||
| No | 24 | 8.9 | 1 | |||
| Yes | 59 | 3.7 | 2.0 | 1.1-3.8 | ||
| Liver metastases at BM diagnosis | ||||||
| No | 47 | 4.1 | 0.17 | |||
| Yes | 36 | 3.6 | ||||
| CD3 T-cell infiltration in PT# | 79 | 0.15 | ||||
| CD3 T-cell infiltration in BM# | 31 | 0.91 | ||||
| DGMate score in PT# | 80 | 0.71 | ||||
| DGMate score in BM# | 37 | 0.84 | ||||
| CD3 T-cell infiltration in PT¤ | 0.45 | |||||
| Low | 40 | 3.7 | ||||
| High | 39 | 3.9 | ||||
| CD3 T-cell infiltration in BM¤ | 0.23 | |||||
| Low | 14 | 10.6 | ||||
| High | 15 | 7.5 | ||||
| DGMate score in PT¤ | 0.78 | |||||
| Low | 40 | 4.1 | ||||
| High | 40 | 3.3 | ||||
| DGMate score in BM¤ | 0.92 | |||||
| Low | 19 | 8.0 | ||||
| High | 18 | 9.8 | ||||
HR, hazard ratio; BM, brain metastasis(es); PT, primary tumor; 95% CI, 95% confidence interval; ECOG PS, Eastern Cooperative Oncology Group score performances status.
*variables included in multivariate analysis.
#analyses as continuous variable.
¤scores split at median.